Allergy Amulet, Inc.

The APPs will support USDH’s expansion throughout Pennsylvania and DelawareEXTON, Pa., Dec. 17, 2024 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the nation’s largest gastroenterology (GI) practices, today announced the addition of 19 new Advanced Practice Providers (APPs) to its network of gastroenterology specialists in 2024. The APPs will practice at various locations throughout Pennsylvania and Delaware, spanning multiple counties, including Berks, Blair, Bucks, Chester, Cumberland, Lancaster, and Washington. Joining USDH’s various office locations are: Crystal Boyer, PA-C, Royersford, WyomissingElizabeth Camerino, PA-C, Ephrata, LancasterJulia Colangeli, PA-C, Broomall, Lankenau, RiddleJennifer Grim, CRNP, Ephrata, LancasterLinda Haffelfinger, PA-C, Flourtown, Lansdale-ColmarGabrielle Hocker, PA-C, AltoonaMonique Junker, CRNP, Broomall, Lankenau, RiddleMargaret Krebs, CRNP, Bala Cynwyd, Bensalem, LanghorneCharles Mikulka, PA-C, Ephrata, LancasterGee-Sue Elizabeth Park, PA-C, LanghorneJulia Quigley, PA-C, Broomall, Malvern, RiddleAlexandra Quinn, CRNP, NewarkJasmine Rodriguez, PA-C, Royersford, WyomissingGloria Schaeffer, CRNP, CarlisleJoan Taddei, PA-C, MalvernAlexandra Thurston, CRNP, Broomall, RiddleCarrie Weiss, CRNP, Bensalem, LanghorneBrian Scott Winfield, PA-C, NewarkKristen Zima, PA-C, Washington “As the demand for high-quality gastroenterological care continues to rise and the number of practicing physicians remains limited, we are thrilled to welcome these highly skilled APPs to our team,” said Dr. Louis La Luna, Chief Medical Officer of US Digestive Health. “Their expertise will allow us to expand access to essential services, ensuring that our patients and communities receive the care they need when they need it.” USDH is the leading gastroenterology practice in the Northeast and one of the largest in the United States, with more than 40 locations and over 250 providers currently working throughout Southeastern, Central, and Southwestern Pennsylvania and Delaware. Patients can book appointments with USDH’s new APPs by visiting the USDH website. About US Digestive Health US Digestive Health (USDH) is the leading gastroenterology practice in the Northeast and one of the largest in the United States, managed by US Digestive Health Management (USDHM). USDH and USDHM were formed in 2019 by Amulet Capital Partners, LP ("Amulet"), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. USDH aims to deliver high-value, patient-centric digestive healthcare by bringing new insight into the care, treatment, and prevention of digestive health disorders. USDH consists of more than 40 locations, 24 ambulatory surgery centers, over 250 GI providers, and more than 1,250 employees throughout Southeastern, Central, and Southwestern Pennsylvania and Delaware. Media Contact: Lauren StraloPR Directorlstralo@levlane.com484-747-0172www.levlane.com

New five-year outcomes presented at American Heart Association's Scientific Sessions show that Amplatzer Amulet helps more patients avoid long-term use of blood-thinning medication compared to Watchman‡ Simultaneously published in the Journal of the American College of Cardiology, the findings show that superior closure of the left atrial appendage (LAA) was achieved with Amplatzer Amulet Amplatzer Amulet is a closure device used in the heart that helps prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with atrial fibrillation, the most common type of irregular heart rhythm ABBOTT PARK, Ill., Nov. 18, 2024 — Abbott today announced late-breaking data for the Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. The new five-year findings demonstrate that Abbott's Amplatzer Amulet helps more patients avoid long-term use of blood-thinning medication compared to the Watchman‡ device. The findings provide physicians with valuable insights into the long-term benefits of the Amplatzer Amulet for patients at risk of stroke due to AFib. Key factors, such as long-lasting outcomes, effective LAA closure and a reduced need for blood-thinning medication, are critical considerations for physicians and patients when choosing an LAA closure approach. The results were presented at the American Heart Association's Scientific Sessions 2024 in Chicago (Nov. 16-18, 2024). These data were simultaneously published in the Journal of the American   College of Cardiology. Key Findings From the Amplatzer Amulet IDE Trial Consisting of more than 1,800 patients, the Amulet IDE trial is the largest, randomized LAA occlusion study to date comparing the Abbott Amplatzer Amulet LAA Occluder head-to-head with Boston Scientific's Watchman device. Five-year findings from the prospective, global clinical trial demonstrated: A statistically significant higher percentage of Amplatzer Amulet patients were not using blood-thinner medication compared to Watchman patients (94.0% vs. 90.9%). A statistically significant lower number of fatal or disabling strokes with Amulet (22 vs. 39). Statistically significant data showing superior closure of the LAA being achieved with Amulet compared to Watchman (89.2% vs. 83.3%). "Because blood thinners may cause excessive bleeding and side effects like nausea or dizziness, we as physicians want to avoid these medications for our patients following an LAA closure procedure," said Dhanunjaya Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health, who served as principal investigator for the Amulet IDE trial. "With the five-year findings from Abbott's Amulet IDE study, doctors can even more confidently offer AFib patients the minimally invasive Amulet device that not only closes the LAA and reduces their risk of stroke, but can also keep them off blood-thinning medication long-term." Superior LAA Closure & Stroke Risk Reduction AFib is a condition that disrupts the heart's ability to effectively pump blood and can lead to blood clots forming in the LAA, a small pouch connected to the upper chamber of the heart. If clots reach the blood stream, they can travel to the brain and cause a stroke. This risk may be reduced by blood-thinning medication. For patients with AFib who are unable to take blood-thinning medication long term, physicians may opt for occlusion (or closure) of the LAA through a minimally invasive procedure using devices like Abbott's Amplatzer Amulet to seal off the LAA entirely and reduce the risk of stroke. Long-term medication to reduce the risk of stroke is not a viable option for many patients due to side-effects such as bleeding. The Amulet device offers a new solution for these individuals, featuring a dual-seal design that can effectively treat nearly all LAA structures and achieve permanent closure.  "For years, doctors and their patients only had one minimally invasive option to close the LAA," said Sandra Lesenfants, senior vice president of Abbott's structural heart business. "The Amplatzer Amulet redefined LAA closure by offering dual-seal technology that completely and immediately seals the LAA without requiring blood-thinning medication following the procedure. These data reinforce that the Amulet device is safe and effective, and also, importantly, that it's helping people enjoy their lives and worry less about the risk of having a stroke." The Amplatzer Amulet LAA Occluder has been approved for use in more than 80 countries, including in Europe, the United States, Canada and Australia, since its initial CE Mark approval in 2013 and FDA approval in 2021. For U.S. important safety information on the Amplatzer Amulet LAA Occluder, visit https://abbo.tt/AmuletISI. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third-party trademark, which is property of its respective owner. © 2024 Abbott. All Rights Reserved.

GREENWICH, Conn.--( BUSINESS WIRE )--Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, today announced it has acquired the Genetics & IVF Institute (“GIVF” or the “ Company), a leading provider of reproductive tissue banking and related reproductive technology services. The transaction includes significant co-investment from a consortium of Amulet Limited Partners. Financial terms of the transaction were not disclosed. Founded in 1984, GIVF has grown into one of the world’s largest providers of frozen donor sperm and frozen donor eggs and a leading provider of cryostorage for embryos, sperm and eggs in the United States. The Company currently operates leading multi-national brands including Fairfax Cryobank and Fairfax Eggbank. Following the transaction, GIVF will continue to be led by Co-CEOs Nadeem Malik and Sean Swindell. “ Over the past 40 years, GIVF has established itself as a critical resource within the fertility space, and we are thrilled to partner with Nadeem and Sean to drive the Company’s next phase of growth,” said Jay Rose, Managing Partner of Amulet. “ As investors in the fertility industry for nearly five years, we have deep respect for all that GIVF has accomplished and, as our second platform investment in the space, we believe we are uniquely positioned to support the company’s long-term objectives. We look forward to working closely with the Company to capitalize on its momentum and serve patients across the U.S. and abroad, as well as partner with leading fertility clinics throughout the country.” “ This is an exciting milestone for GIVF, one which underscores the importance of our work and serves as a testament to our team’s innovative spirit and dedication to client care,” said Nadeem Malik, Co-CEO of GIVF. “ As the need for fertility and reproductive healthcare services only continues to rise, it is more important than ever that we are positioned to invest in our team, platform, and scale in order to help more families. We know Amulet’s investment will support that mission, and we look forward to working with their team and benefitting from their resources and expertise as we enter our next stage of growth.” “ GIVF has played a critical role in meeting the significant demand for fertility and fertility-adjacent services,” said Sam Brinkley, Principal at Amulet. “ Under the leadership of Sean and Nadeem, the Company has become an integral component in thousands of families’ journeys to realize the joys of family building. At such a critical moment for fertility patient care, we are honored to partner with the GIVF team and provide them with the resources to expand access to thousands of hopeful parents in need of donor tissue and similar reproductive services.” “ This is all about building on our four-decade heritage of providing compassionate care,” said Sean Swindell, Co-CEO of GIVF. “ Through this transaction, we gain an investment partner that deeply understands our business, shares our mission, vision, and values, and positions us to further develop and expand our service offerings to deliver greater value for the patients we serve.” This is Amulet’s third investment out of Amulet Capital Fund III, following its partnership with minds + assembly, a full-service, design-centric agency and commercialization platform servicing the pharmaceutical, biotech and digital health industries; and Alliance Clinical Network, a leading comprehensive clinical platform serving patients, pharmaceutical sponsors and CROs across numerous clinical areas. About Amulet Capital Partners Amulet Capital Partners is a middle-market private equity investment firm based in Greenwich, CT, and Walnut Creek, CA, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in healthcare companies. Amulet focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size between $50 million to $150 million. For additional information, please visit www.amuletcapital.com .